Intravaginal Gel for Bacterial Vaginosis Recurrence
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for bacterial vaginosis (BV) often fail to effectively address the condition and its recurrence, as they do not adequately restore the vaginal microbiome balance, leading to persistent symptoms and high recurrence rates.
Innovation Solution
A composition comprising a polymer thickener, L-lactic acid, and a preservative, administered intravaginally, which helps lower vaginal pH and restore a healthy vaginal microbiome, thereby treating and preventing BV.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional treatments are used for bacterial vaginosis, then the treatment process is simple, but the recurrence rate is high and the microbiome balance is not restored
Solution Approach 1:
The patent uses a composite treatment composition containing multiple active ingredients (lactic acid, hydrogen peroxide, and probiotics) working together to treat BV. This multi-component formulation addresses the high recurrence rate by simultaneously lowering pH, producing antimicrobial effects, and restoring microbiome balance, while the ingredients are combined in a single intravaginal gel or suppository that maintains practical ease of use.
2Ease of operation
If antibiotics are used to treat BV, then the immediate symptoms are reduced, but the vaginal microbiome balance deteriorates further
Solution Approach 1:
The patent converts the harmful effect of disrupted microbiome into a benefit by actively restoring it through probiotic incorporation. The treatment not only addresses symptoms through lactic acid-induced pH lowering and hydrogen peroxide antimicrobial action, but also simultaneously rebuilds healthy vaginal flora with Lactobacillus probiotics, turning the potential harm of microbiome disruption into an opportunity for restoration.
Solution Approach 2:
The patent fundamentally changes the treatment parameter from antibacterial killing to pH-mediated bacterial selection. By lowering vaginal pH to 3.5-4.5 through lactic acid, the treatment creates an environment that naturally suppresses pathogenic bacteria while favoring Lactobacillus growth, thereby resolving symptoms while restoring microbiome balance without using broad-spectrum antibiotics.
3Reliability
If the vaginal pH is not maintained at acidic levels, then the treatment is simple, but BV symptoms persist and recur
Solution Approach 1:
The patent employs self-service pH maintenance through the incorporation of lactic acid and probiotics that actively produce additional lactic acid. The lactic acid in the formulation immediately lowers pH upon application, while the probiotic Lactobacillus bacteria continuously produce lactic acid through fermentation of glycogen, thereby self-maintaining the acidic pH environment (3.5-4.5) needed to prevent BV recurrence without requiring external intervention.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively ameliorates BV symptoms, reduces recurrence rates, and maintains a healthy vaginal microbiome, providing a more sustainable treatment solution compared to traditional methods.
Implementation Method 1
administration of the composition lowers vaginal pH of the subject, thereby treating the BV
Data Source
AI summary
Described herein are methods of reducing the risk of recurrence of bacterial vaginosis by intravaginal administration of compositions comprising L-lactic acid, polymer thickener, and preservative.